Cybin to present 12-month phase 2 data for cyb003 in major depressive disorder on november 18, 2024

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on monday, november 18, 2024 at 8:00 a.m. et. the event will be hosted by cybin's chief executive officer, doug drysdale, and cybin's chief medical officer,.
CYBN Ratings Summary
CYBN Quant Ranking